First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery
Cambridge, UK, 26 April 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today introduced its PhysioMimix™ ‘in-a-box’ reagent kit for Non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). Previously only accessible via its contract research services, CN Bio’s best-in-class NASH in vitro model supports the urgent development of therapeutics to treat this emerging global healthcare priority.
Despite research efforts to combat the growing prevalence of NASH, to-date, there are no regulatory approved therapeutics due to the inability of traditional in vivo animal experiment approaches to predict the human response to this complex disease. In conjunction with CN Bio’s PhysioMimix MPS, the NASH-in-a-box (NIAB) kit provides researchers with in-house capabilities to gain physiologically relevant insights into the mechanism of disease, human drug efficacy and safety toxicology. The assay addresses the human-relevance limitations of existing approaches, bridging the gap between human 2D cell culture and expensive animal models, which are ineffective in mimicking the full disease spectrum. This enables NIAB kit users to generate clinically translatable and predictive data that facilitate more insightful, accurate and cost-effective drug development.
Through its ‘in-a-box’ range, CN Bio aims to fast-track the incorporation of MPS into drug discovery workflows by providing a straightforward and quick route to recreating its industry-proven OOC assays. Within the NIAB kit, new users are guided through a simple to follow, software-based protocol for successfully co-culturing internally-validated primary human hepatocytes, stellate and Kupffer cells. The protocol enables the formation of 3D microtissue structures that accurately emulate the microarchitecture of the human liver. By introducing fatty acids, researchers can recapitulate key NAFLD/NASH disease states: intracellular fat accumulation, inflammation and fibrosis1. Once created, the model enables the precise mechanistic effects of drugs (of any modality) and disease to be investigated via high content, clinically translatable end-point measurements.
Dr David Hughes, CEO, CN Bio, said: “NASH-in-a-box enables CN Bio to expand our market reach from those who prefer to outsource their testing to our laboratories, to those who would rather develop in house capabilities. As the first in our ‘in-a-box’ range, the launch of the NASH kit represents a significant step towards the widespread adoption of Organ-on-a-chip technology within the drug discovery industry. Consequently, we believe this product will enable discovery programmes targeting this disease which is a large and growing burden on healthcare systems, yet lacks any approved therapies.”
Dr Ovidiu Novac, Senior Scientist for CN Bio, commented: “This new product demonstrates the full advantages of our microphysiological systems, providing scientists with access to easy-to-use, yet best-in-class liver models in their own labs, streamlining the process and making it far quicker and more cost effective. We believe this will allow for more thorough and accurate testing during the drug development process, which will increase the likelihood of much-needed new NASH drugs to make it to market.”
For more information, please visit: https://cn-bio.com/nash-in-a-box/
References:
1. Kostrzewski, T., Snow, S., Battle, A.L. et al. Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. Commun Biol 4, 1080 (2021). https://doi.org/10.1038/s42003-021-02616-x